Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Holdings Increased by IFM Investors Pty Ltd

IFM Investors Pty Ltd boosted its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 8.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 74,988 shares of the medical equipment provider's stock after acquiring an additional 6,061 shares during the period. IFM Investors Pty Ltd's holdings in Intuitive Surgical were worth $36,839,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. GF Fund Management CO. LTD. raised its stake in shares of Intuitive Surgical by 1.8% in the 1st quarter. GF Fund Management CO. LTD. now owns 75,636 shares of the medical equipment provider's stock valued at $37,460,000 after acquiring an additional 1,305 shares during the period. OneDigital Investment Advisors LLC raised its stake in shares of Intuitive Surgical by 3.9% in the 1st quarter. OneDigital Investment Advisors LLC now owns 15,535 shares of the medical equipment provider's stock valued at $7,694,000 after acquiring an additional 588 shares during the period. 44 Wealth Management LLC raised its stake in shares of Intuitive Surgical by 3.9% in the 1st quarter. 44 Wealth Management LLC now owns 1,112 shares of the medical equipment provider's stock valued at $551,000 after acquiring an additional 42 shares during the period. Fisher Funds Management LTD raised its stake in shares of Intuitive Surgical by 22.5% in the 1st quarter. Fisher Funds Management LTD now owns 203,604 shares of the medical equipment provider's stock valued at $100,839,000 after acquiring an additional 37,446 shares during the period. Finally, Avantax Planning Partners Inc. raised its stake in shares of Intuitive Surgical by 9.6% in the 1st quarter. Avantax Planning Partners Inc. now owns 1,152 shares of the medical equipment provider's stock valued at $571,000 after acquiring an additional 101 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Intuitive Surgical Price Performance

ISRG traded down $9.76 during trading on Monday, hitting $534.71. The company had a trading volume of 1,191,600 shares, compared to its average volume of 1,670,783. The company has a market cap of $191.65 billion, a PE ratio of 78.40, a P/E/G ratio of 5.78 and a beta of 1.64. The business has a 50-day moving average of $537.11 and a 200-day moving average of $536.92. Intuitive Surgical, Inc. has a 1-year low of $413.82 and a 1-year high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.71 by $0.10. Intuitive Surgical had a net margin of 28.41% and a return on equity of 14.43%. The firm had revenue of $2.25 billion for the quarter, compared to analysts' expectations of $2.19 billion. During the same period in the prior year, the company posted $1.50 earnings per share. Research analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Gary Loeb sold 1,700 shares of the company's stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $513.18, for a total value of $872,406.00. Following the completion of the sale, the executive vice president directly owned 2,245 shares of the company's stock, valued at approximately $1,152,089.10. This represents a 43.09% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Mark Brosius sold 216 shares of the company's stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the sale, the senior vice president directly owned 907 shares of the company's stock, valued at $510,740.77. The trade was a 19.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 4,998 shares of company stock worth $2,611,577. 0.70% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of brokerages have commented on ISRG. Citigroup reissued a "buy" rating and issued a $650.00 price objective (up from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. Erste Group Bank upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Thursday, June 5th. BTIG Research set a $560.00 target price on shares of Intuitive Surgical and gave the stock a "buy" rating in a research note on Monday, April 14th. Piper Sandler cut their price target on shares of Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Finally, Evercore ISI cut their price target on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a report on Wednesday, April 23rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $588.95.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.